These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 2040803)
1. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. Peeters CC; Tenbergen-Meekes AM; Evenberg DE; Poolman JT; Zegers BJ; Rijkers GT J Immunol; 1991 Jun; 146(12):4308-14. PubMed ID: 2040803 [TBL] [Abstract][Full Text] [Related]
2. Induction of anti-pneumococcal cell wall polysaccharide antibodies by type 4 pneumococcal polysaccharide-protein conjugates. Peeters C; Tenbergen-Meekes AM; Poolmann J; Zegers B; Rijkers G Med Microbiol Immunol; 1992; 181(1):35-42. PubMed ID: 1579084 [TBL] [Abstract][Full Text] [Related]
3. Models for assessing the effect of toxicants on immunocompetence in mice. II. Effect of cyclophosphamide on the antibody responses to type III pneumococcal polysaccharide and tetanus toxoid in BALB/c female mice. Speirs RS; Benson RW; Knowles BJ; Roberts D J Environ Pathol Toxicol; 1978; 1(6):791-812. PubMed ID: 32218 [TBL] [Abstract][Full Text] [Related]
4. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. Paoletti LC; Kasper DL; Michon F; DiFabio J; Jennings HJ; Tosteson TD; Wessels MR J Clin Invest; 1992 Jan; 89(1):203-9. PubMed ID: 1729272 [TBL] [Abstract][Full Text] [Related]
5. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Peeters CC; Tenbergen-Meekes AM; Poolman JT; Beurret M; Zegers BJ; Rijkers GT Infect Immun; 1991 Oct; 59(10):3504-10. PubMed ID: 1894357 [TBL] [Abstract][Full Text] [Related]
7. Type 6 and 19 pneumococcal polysaccharides coupled to erythrocytes elicit pneumococcal cell wall-specific primary IgM responses and capsular polysaccharide-specific secondary IgG responses. Milligan GN; Fairchild RL; Sterner KE; Braley-Mullen H Eur J Immunol; 1990 Mar; 20(3):595-603. PubMed ID: 2318251 [TBL] [Abstract][Full Text] [Related]
8. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Barrett DJ; Ayoub EM Clin Exp Immunol; 1986 Jan; 63(1):127-34. PubMed ID: 3955880 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Lagergard T; Shiloach J; Robbins JB; Schneerson R Infect Immun; 1990 Mar; 58(3):687-94. PubMed ID: 2407652 [TBL] [Abstract][Full Text] [Related]
10. Characteristics of two types of meningococcal group C polysaccharide conjugates using tetanus toxoid as carrier protein. Beuvery EC; Roy R; Kanhai V; Jennings HJ Dev Biol Stand; 1986; 65():197-204. PubMed ID: 3104115 [TBL] [Abstract][Full Text] [Related]
11. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. Jennings HJ; Lugowski C J Immunol; 1981 Sep; 127(3):1011-8. PubMed ID: 6790606 [TBL] [Abstract][Full Text] [Related]
12. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization. Cuello M; Cabrera O; Martinez I; Del Campo JM; Camaraza MA; Sotolongo F; Pérez O; Sierra G Vaccine; 2007 Feb; 25(10):1798-805. PubMed ID: 17240485 [TBL] [Abstract][Full Text] [Related]
13. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. Jennings HJ; Roy R; Gamian A J Immunol; 1986 Sep; 137(5):1708-13. PubMed ID: 3091688 [TBL] [Abstract][Full Text] [Related]
14. Kinetics of the antibody response to type III pneumococcal polysaccharide. II. Factors influencing the serum antibody levels after immunization with an optimally immunogenic dose of antigen. Jones JM; Amsbaugh DF; Prescott B J Immunol; 1976 Jan; 116(1):52-64. PubMed ID: 1446 [TBL] [Abstract][Full Text] [Related]
15. Memory B and T cell responses induced by serotype 4 Streptococcus pneumoniae vaccines: longitudinal analysis comparing responses elicited by free polysaccharide, conjugate and carrier. Deauvieau F; Dussurgey S; Rossignol D; de Montfort A; Burdin N; Guy B Vaccine; 2009 Dec; 28(2):576-82. PubMed ID: 19878751 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response. Rodriguez ME; van den Dobbelsteen GP; Oomen LA; de Weers O; van Buren L; Beurret M; Poolman JT; Hoogerhout P Vaccine; 1998 Dec; 16(20):1941-9. PubMed ID: 9796048 [TBL] [Abstract][Full Text] [Related]
17. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides undergo normal isotype switching after immunization with polysaccharide-protein conjugate vaccines. Shapiro DA; Threadgill DS; Copfer MJ; Corey DA; McCool TL; McCormick LL; Magnuson TR; Greenspan NS; Schreiber JR J Immunol; 1998 Oct; 161(7):3393-9. PubMed ID: 9759856 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide. Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445 [TBL] [Abstract][Full Text] [Related]